Fabhalta lowered chance of development to kidney failure by 43% in APPLAUSE-IgAN study140.7% of sufferers on Fabhalta demonstrated sustained discount of protein in urine over two years1Fabhalta granted precedence evaluate by FDA for conventional approval
Basel, March 29, 2026 – Novartis at this time introduced last two-year outcomes from the Section III APPLAUSE‑IgAN research of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically vital, clinically significant enchancment in estimated glomerular filtration price (eGFR) slope, a key marker of kidney perform, in contrast with placebo1. Fabhalta constantly outperformed placebo throughout key kidney outcomes over two years, demonstrating a slowing of illness development and the potential to protect kidney perform in IgAN1.
The outcomes have been revealed within the New England Journal of Drugs and concurrently offered as late‑breaking knowledge on the 2026 World Congress of Nephrology (WCN).
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time,” mentioned Vlado Perkovic, MD, Professor of Drugs and Provost, College of New South Wales, and Steering Committee Co‑Chair of the APPLAUSE‑IgAN research. “These results are important because they show that Fabhalta can reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden.”
Key efficacy outcomes over two years1
More Read
Endpoint Fabhalta Placebo Impact vs. placebo Kidney perform
(eGFR slope)
–3.10 mL/min/1.73 m²/yr
More Read
–6.12 mL/min/1.73 m²/yr
3.02 mL/min/1.73 m2/yr (49.3% slower decline)
Composite kidney failure occasions*† 21.4% 33.5% HR 0.57 (43% decrease chance) Proteinuria†
More Read
(24-hour UPCR <1g/g)
40.7% achieved goal
23.7% achieved goal
—
*Composite kidney failure endpoint: reaching both sustained ≥30% decline in eGFR relative to baseline, sustained eGFR <15 mL/min/1.73 m², initiation of upkeep dialysis, kidney transplant, or loss of life from kidney failure†As measured by share of sufferers
“The two-year results demonstrate that Fabhalta consistently and meaningfully slows kidney function decline in high-risk patients with IgAN,” mentioned Ruchira Glaser, MD, MS, World Head, Cardiovascular, Renal and Metabolic Growth, Novartis. “This progress reflects years of focused research and supports our efforts to advance more targeted treatment options to help preserve kidney health in people living with IgAN.”
The security profile of Fabhalta over two years was in keeping with earlier findings. Charges of antagonistic occasions and remedy discontinuation have been low and related between Fabhalta and placebo1,2.
Fabhalta acquired accelerated approval within the U.S. and China for proteinuria discount in adults with IgAN based mostly on knowledge from a prespecified interim evaluation of the APPLAUSE-IgAN study2,3. The 2-year knowledge have been submitted to the U.S. Meals and Drug Administration for conventional approval. Fabhalta was granted precedence evaluate based mostly on the novel mode of motion and the energy of the information. Alongside Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which additionally contains Vanrafia® (atrasentan) and investigational compound zigakibart.
About IgANIgAN is a progressive autoimmune kidney illness, with roughly 25 folks per million worldwide newly identified every year4,5. IgAN is very debilitating because it results in irritation within the small filters of the kidneys, extra protein in urine, and a gradual decline in eGFR6. As much as 50% of sufferers with persistent proteinuria progress to kidney failure inside 10 to twenty years of analysis, usually requiring dialysis or kidney transplantation as a part of long-term illness management5-10.
Moreover, folks dwelling with IgAN usually face psychological and social challenges6-9. Supportive care has not addressed the underlying causes of the illness and sometimes fails to gradual illness development, reinforcing the necessity for extra focused therapies for IgAN7-12.
About APPLAUSE-IgANAPPLAUSE-IgAN (NCT04578834) is a world, randomized, double-blind, placebo-controlled Section III research evaluating Fabhalta in adults with biopsy-confirmed IgAN and chronic proteinuria regardless of optimized supportive care. Sufferers have been randomized 1:1 to obtain Fabhalta or placebo and have been adopted for as much as 24 months11. The first endpoint was the annualized complete eGFR slope over 24 months. Key secondary endpoints included time to first composite kidney failure occasion and adjustments in proteinuria over 9 months1.
The commonest antagonistic occasions with Fabhalta have been primarily mild-to-moderate infections (comparable to COVID-19 and higher respiratory tract an infection), headache, diarrhea, and hyperlipidemia, with general antagonistic occasion charges corresponding to placebo1.
About Fabhalta® (iptacopan)Fabhalta (iptacopan) is an oral Issue B inhibitor designed to selectively goal the choice complement pathway, certainly one of a number of key drivers of irritation and kidney harm in IgAN4,12,13. By inhibiting Issue B, Fabhalta goals to scale back ongoing complement-mediated harm and gradual illness development. Fabhalta has acquired regulatory approvals in a number of complement-mediated ailments, together with IgAN, and is being evaluated throughout a variety of uncommon kidney circumstances.
Novartis’ dedication to kidney diseasesBuilding on a legacy of greater than 40 years that started in transplant, Novartis is on a mission to empower breakthroughs and remodel care in kidney well being, beginning with kidney circumstances which have vital unmet want.
Traditionally, these circumstances have had significantly much less funding and analysis, resulting in a remedy panorama largely targeted on reactive or end-stage illness administration, usually with vital bodily, emotional, and monetary burdens. Our portfolio targets the underlying causes of illness, with an purpose to guard kidney well being and delay or stop dialysis and/or transplantation. Our objective is to assist sufferers get again to dwelling life on their phrases – whether or not at work, at school, or with family members, and by partnering with sufferers, advocates, clinicians and policymakers, we purpose to lift consciousness, speed up analysis, and get sufferers the correct care, sooner.
DisclaimerThis press launch incorporates forward-looking statements throughout the that means of the USA Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements can usually be recognized by phrases comparable to “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or related phrases, or by specific or implied discussions concerning potential advertising and marketing approvals, new indications or labeling for the investigational or authorized merchandise described on this press launch, or concerning potential future revenues from such merchandise. You shouldn’t place undue reliance on these statements. Such forward-looking statements are based mostly on our present beliefs and expectations concerning future occasions, and are topic to vital recognized and unknown dangers and uncertainties. Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might range materially from these set forth within the forward-looking statements. There might be no assure that the investigational or authorized merchandise described on this press launch shall be submitted or authorized on the market or for any extra indications or labeling in any market, or at any specific time. Nor can there be any assure that such merchandise shall be commercially profitable sooner or later. Particularly, our expectations concerning such merchandise could possibly be affected by, amongst different issues, the uncertainties inherent in analysis and improvement, together with medical trial outcomes and extra evaluation of present medical knowledge; regulatory actions or delays or authorities regulation usually; world tendencies towards well being care price containment, together with authorities, payor and common public pricing and reimbursement pressures and necessities for elevated pricing transparency; our skill to acquire or keep proprietary mental property safety; the actual prescribing preferences of physicians and sufferers; common political, financial and enterprise circumstances, together with the consequences of and efforts to mitigate pandemic ailments; security, high quality, knowledge integrity or manufacturing points; potential or precise knowledge safety and knowledge privateness breaches, or disruptions of our data expertise programs, and different dangers and components referred to in Novartis AG’s present Kind 20-F on file with the US Securities and Trade Fee. Novartis is offering the data on this press launch as of this date and doesn’t undertake any obligation to replace any forward-looking statements contained on this press launch on account of new data, future occasions or in any other case.
About Novartis Novartis is an modern medicines firm. Each day, we work to reimagine drugs to enhance and prolong folks’s lives in order that sufferers, healthcare professionals and societies are empowered within the face of significant illness. Our medicines attain greater than 300 million folks worldwide.
Reimagine drugs with us: Go to us at https://www.novartis.com and join with us on LinkedIn, Fb, X/Twitter and Instagram.
References
Novartis. Knowledge on fileNovartis Prescription drugs Company. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the primary and solely complement inhibitor for the discount of proteinuria in main IgA nephropathy (IgAN) (2024). Out there at: https://www.novartis.com/information/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan. Accessed March 2026 Novartis China. Novartis’ modern drugs Fabhalta® (iptacopan) authorized in China for a brand new indication. Novartis China web site (in Mandarin). Out there at: https://www.novartis.com.cn/information/nuohuazaiyingshenzangjibingzhiliaolingyulichengbeichuangxinyaowufeihedayansuanyipukepanjiaonangigashenbingshiyingzhengzaizhongguohuopi. Accessed March 2026Rizk DV, Maillard N, Julian BA, et al. The rising position of complement proteins as a goal for remedy of IgA nephropathy. Entrance Immunol 2019;10:504.Cheung C, Barratt J. The quickly altering remedy panorama of IgA nephropathy. Semin Nephrol. 2025;44:151573.Kwon CS, Daniele P, Forsythe A et al. A scientific literature evaluate of the epidemiology, health-related high quality of life impression, and financial burden of immunoglobulin a nephropathy. J Well being Econ Outcomes Res. 2021;8:36–45.Pitcher D, Braddon F, Hendry B et al. Lengthy-term outcomes in IgAN. Clin J Am Soc Nephrol. 2023;18:727–8.Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Lengthy-term consequence of immunoglobulin A (IgA) nephropathy: a single middle expertise. PLoS One. Nationwide Kidney Basis. The voice of the affected person (2020). Out there at: https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf. Accessed March 2026.Kidney Illness: Bettering World Outcomes (KDIGO) Glomerular Ailments Work Group. KDIGO 2021 Medical Follow Guideline for the Administration of Glomerular Ailments. Kidney Int. 2021;100:S1–276.Clinicaltrials.gov. NCT04578834. Examine of Efficacy and Security of LNP023 in Major IgA Nephropathy Sufferers (APPLAUSE-IgAN). Out there at: https://clinicaltrials.gov/research/NCT04578834. Accessed March 2026.Perkovic V, Barratt J, Rovin B, et al. Various complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543.Chiu YL, Lin WC, Shu KH, et al. Various complement pathway is activated and related to galactose-deficient IgA(1) antibody in IgA nephropathy sufferers. Entrance Immunol 2021;12:638309.
# # #
